Table. Input characteristics and direct treatment costs estimated for pulmonary drug-susceptible TB treatment, United States*.
| Characteristic |
4-month regimen |
|
6-month regimen |
||
|---|---|---|---|---|---|
| Intensive phase |
Continuation phase |
Intensive phase |
Continuation phase |
||
| Time (doses) |
8 wks (56 doses) |
9 wks (63 doses) |
|
8 wks (56 doses) |
18 wks (126 doses) |
| Anti-TB medications |
Isoniazid 300 mg, rifapentine 1,200 mg, pyrazinamide 2,000 mg, moxifloxacin 400 mg |
Isoniazid 300 mg, rifapentine 1,200 mg, moxifloxacin 400 mg |
|
Isoniazid 300 mg, rifampin 600 mg, pyrazinamide 2,000 mg, ethambutol 1,600 mg |
Isoniazid 300 mg, rifampin 600 mg |
| No. daily pills† |
15 |
11 |
|
12 |
4 |
| No. DOT clinic visits‡ |
40 |
45 |
|
40 |
90 |
| Costs§ | |||||
| Examination | 370 | 402 | |||
| Clinic supply | 74 | 80 | |||
| Medication | 3,023 | 1,546 | |||
| DOT | 2,354 | 3,600 | |||
| Subtotal outpatient costs | 5,820 | 5,628 | |||
| Subtotal inpatient costs¶ | 17,432 | 17,432 | |||
| Total estimated direct treatment costs | 23,252 |
23,060 |
|||
*DOT, directly observed therapy; TB, tuberculosis. †Pill count assumed anti-TB medications plus 1 daily pyridoxine (vitamin B6) tablet for persons taking isoniazid. ‡DOT administered 5 of 7 weekly doses throughout treatment. §In 2021 US dollars. ¶Inpatient costs assumed equivalent across regimens because TB outcomes and adverse events were similar according to clinical trial data.